IR-MED's Key Clinical and Media Milestones

Rhea-AI Summary

IR-MED (OTCQB: IRME) announced a series of visibility and clinical milestones on October 27, 2025 highlighting its PressureSafe™ AI-powered infrared spectroscopy platform for pressure injuries and diabetic ulcers.

Key events: a podium presentation at Magnet & Pathway 2025 (Oct 7, Atlanta) where Dr. Mary Lee Poter presented clinical research titled "Enhancing Skin Assessment: Infrared Spectroscopy Across All Skin Tones" reporting high sensitivity in assessing pressure injuries across diverse skin tones; a presentation to investors at the NIBA conference (Sept 16-17, Fort Lauderdale) outlining commercialization progress; and a national TV feature on Israel's Channel 10 (Oct 5) with Dr. Yaniv Cohen demonstrating the platform.

The company said these appearances expanded clinical, investment, and media awareness for PressureSafe™ and its goal to improve equitable wound assessment.

PressureSafe(TM) clinical results presented to global nursing leaders; the Company engages with U.S. investment community and national media in parallel visibility push

Rosh Pina, Israel--(Newsfile Corp. - October 27, 2025) - IR-Med Inc. (OTCQB: IRME), (the "Company" or "IR-Med"), a medical technology company developing a non-invasive, AI-powered infrared spectroscopy platform for the assessment of pressure injuries and diabetic ulcers, today announced a series of recent milestones that highlight the Company's expanding visibility within the healthcare, investment, and media communities.

Podium Presentation at Magnet & Pathway 2025 Conference - October 7, 2025, Atlanta, GA^[1]

IR-MED's technology was showcased at the Magnet & Pathway 2025 Conference, the world's largest professional nursing event, after being selected by the Scientific Committee for a podium presentation. During the session, Dr. Mary Lee Poter, PhD, principal investigator from HCA Methodist Metropolitan Hospital, presented clinical research using PressureSafe™ titled "Enhancing Skin Assessment: Infrared Spectroscopy Across All Skin Tones."

The study demonstrated how near-infrared spectroscopy, combined with artificial intelligence ("AI") trained on diverse skin tones, provides high sensitivity in assessing pressure injuries-particularly among patients with darker skin-helping clinicians detect early-stage wounds and improve patient outcomes. The presentation received strong interest from attendees and was described by the conference as "an interesting and much-needed product."

Presentation at the National Investment Banking Association (NIBA) Conference - September 16-17, 2025, Fort Lauderdale, FL^[2]

At the 151st NIBA Conference, IR-MED's executive team presented its AI- and infrared-based diagnostic platform to a distinguished audience of public company executives, investment professionals, and capital market professionals. The Company outlined its progress toward commercialization and its potential to redefine non-invasive skin assessment.

This appearance broadened IR-MED's exposure to the U.S. investment banking community.

Feature on Israel's Channel 10 National Economic Program "The Next Big Thing" - October 5, 2025

IR-MED's innovation was also featured on Channel 10's national economic program, "The Next Big Thing," hosted by Danny Roup. Dr. Yaniv Cohen, Co-Founder and Chief Scientific Officer, presented the Company's PressureSafe™ platform, demonstrating how its AI and infrared technology enable clinicians to assess subdermal tissue health and support equitable wound care for patients of all skin tones.

The televised segment reached a nationwide Israeli audience, further strengthening awareness of IR-MED's mission to improve skin assessment and advance patient safety through cutting-edge technology.

"These recent appearances - across clinical, investment, and media platforms - reflect IR-MED's recognition within the healthcare community," said Ran Ziskind, Chief Executive Officer of IR-MED. "We are encouraged by the interest in our vision to transform skin assessment through AI and infrared innovation."

About IR-MED

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis platform technology as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI based process to provide healthcare professionals with decision support in the assessment of various medical conditions.

PressureSafe™, the company's first platform product, is a handheld device designed to revolutionize the assessment of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe offers healthcare professionals a real-time evaluation of skin , regardless of patient skin tone. The potential assessment of pressure injuries using PressureSafe holds significant promise in addressing this widespread healthcare challenge and potentially reducing its burden worldwide.

IR-MED holds patents protecting its innovation in noninvasive tissue assessment.

PressureSafe is currently undergoing usability studies at multiple medical centers and is not yet available for commercial use.

Safe Harbor Statement / Forward-Looking Statements

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For example, IR-Med is using forward-looking statements when it discusses the progress toward commercialization of the Company's AI and infrared-based diagnostic platform and the Company's potential to redefine non-invasive skin assessment and transform skin assessment through AI and infrared innovation. Statements relating to the future performance of IR-Med are subject to many factors including, but not limited to, the accuracy of the Company's estimates regarding expenses, future revenues, uses of cash, capital requirements and the need for additional financing; the initiation, cost, timing, progress and results of our development activities, usability studies, preclinical studies and any clinical trials that it may be required to undertake; the timing of and the Company's ability to obtain and maintain regulatory approval of our existing product candidates, any product candidates that it may develop, and any related restrictions and/or limitations; the company's plans to research, develop and commercialize its current and future product candidates; the Company's ability to attract collaborators with development, regulatory and commercialization expertise; the company's ability to obtain and maintain intellectual property protection for its product candidates; the Company's ability to successfully commercialize its product candidates; the size and growth of the markets for its product candidates and its ability to serve those markets; the rate and degree of market acceptance of any future products; the success of competing devices that are or may become available; regulatory developments in the United States and other countries; the performance of its third-party suppliers and manufacturers and its ability to obtain alternative sources of raw materials; the impact of global inflationary pressures; its ability to obtain additional financing; use of the proceeds from its securities offerings; any restrictions on its ability to use its net operating loss carry-forwards; the impact of Israel's multi-front war on its results, including potential economic restrictions imposed on and political and military instability in Israel; its ability to attract and retain key personnel, and the other risks identified in our most recent annual report on Form 10-K filed on April 4, 2025 with the Securities and Exchange Commission. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Contact:
Hanover International, Inc.
Kathy Cusumano, President
Contact@ir-medical.com

---

^[1] https://magnetpathwaycon.nursingworld.org/ana-enterprise-research-symposium-1#session-1
^[2] https://nibanet.org/conference/niba-september-16-17-2025-ft-lauderdale-fl-conference/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272069

FAQ

What clinical findings did IRME present at Magnet & Pathway 2025 on October 7, 2025?

IRME presented a study titled "Enhancing Skin Assessment: Infrared Spectroscopy Across All Skin Tones," reporting that near-infrared spectroscopy with AI showed high sensitivity for assessing pressure injuries across diverse skin tones.

How did IRME engage the U.S. investment community in September 2025 (IRME)?

IRME presented its AI- and infrared-based diagnostic platform and commercialization progress at the NIBA conference (Sept 16-17, 2025) to investment bankers and capital market professionals.

When was IRME featured on national Israeli TV and what was shown (IRME)?

IRME was featured on Channel 10's "The Next Big Thing" on Oct 5, 2025, where the PressureSafe™ platform was demonstrated to a nationwide audience.

What clinical population does PressureSafe™ aim to help according to IRME's Oct 27, 2025 release?

PressureSafe™ is designed to assess pressure injuries and diabetic ulcers across all skin tones, with emphasis on improving detection in patients with darker skin.

What commercialization progress did IRME describe to investors at NIBA in 2025 (IRME)?

IRME outlined its progress toward commercialization of its AI and infrared skin-assessment platform and its potential to redefine non-invasive skin assessment.

How do these October 2025 activities affect IRME's visibility for shareholders (IRME)?

The clinical podium, investor presentation, and national TV feature collectively increased IRME's clinical, investment, and media visibility, which the company said supports awareness of PressureSafe™ and its mission.